Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 38, Issue 10, 2011, Pages 2105-2111

  Scarsi, Mirko ^a   Ziglioli, Tamara ^a   Airo, Paolo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Abatacept; CD28 negative T cells; Predictive factors; Remission; Rheumatoid arthritis

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CD28- T CELL; CD4+ CD28- T LYMPHOCYTE; CD8+ CD28- T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY SCORE 28; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD28; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 80053467106     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110386     Document Type: Article

References (19)

1. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011;70:4-7.
2. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15. (Pubitemid 37409707)
3. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996;97:2027-37. (Pubitemid 26143956)
4. Scarsi M, Ziglioli T, Airo' P. Decreased numbers of circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol 2010;37:911-6.
5. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 1997;40:1106-14. (Pubitemid 27242298)
6. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004;109:2744-8. (Pubitemid 38737922)
7. Lake RA, O'Hehir RE, Verhoef A, Lamb JR. CD28 mRNA rapidly decays when activated T cells are functionally anergized with specific peptide. Int Immunol 1993;5:461-6. (Pubitemid 23162515)
8. Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ. Modulation of CD28 expression with anti-tumor necrosis factor-a therapy in rheumatoid arthritis. Arthritis Rheum 2005;52:2996-3003. (Pubitemid 41447078)
9. Linsley PS, Bradshaw J, Urnes M, Grosmaire L, Ledbetter J. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. J Immunol 1993;150:3161-9. (Pubitemid 23129694)
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
11. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
12. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36. (Pubitemid 12142173)
13. Vingerhoets JH, Vanham GL, Kestens LL, Penne GG, Colebunders RL, Vandenbruaene MJ, et al. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 downregulation on CD8+ T cells from HIV-infected subjects. Clin Exp Immunol 1995;100:425-33.
14. Weyand CM, Goronzy JJ. T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol 1999;11:210-7. (Pubitemid 29257639)
15. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-7.
16. Marti L, Golmia R, Golmia AP, Paes AT, Guilhen DD, Moreira-Filho CA, et al. Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann NY Acad Sci 2009;1173:334-42.
17. Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Machalinski B, et al. Therapy with infliximab decreases the CD4+CD28- T cell compartment in peripheral blood in patients with rheumatoid arthritis. Rheumatol Int 2004;24:351-4.
18. Gerli R, Bartoloni-Bocci E, Shoenfeld Y. Effect of tumor necrosis factor a inhibition on CD28 surface expression on CD4+ T cells. Arthritis Rheum 2006;54:3060-1. (Pubitemid 44497790)
19. Papaagoras C, Voulgari PV, Drosos AA. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev 2010;9:574-82.